BD Expanding Safety Needle Technology Platform With Saf-T-Med Buy
This article was originally published in The Gray Sheet
Becton Dickinson plans to initiate marketing feedback studies of Saf-T-Med's Easy Safe retracting needle syringe within 12 months, the company says.
You may also be interested in...
Becton Dickinson's safety engineered "sharps" program with Kaiser Permanente, announced June 16, signals the initial success of a strategy that is expected to carry the company out of its recent warnings of slower growth.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.